ns101
mAbexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 4, 2021 (NCT05143463)
Timeline
Indications
Mechanism of action
- KynureninaseINHIBITOR
KYNU inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07154485 | Phase 2 | Oct 1, 2025 | Hanyang University, Konkuk University, University of Ulsan, Yonsei University |
| NCT06249919 | Phase 1/Phase 2 (Phase 2) | Jan 19, 2024 | Korea University, Neuracle Science Co., LTD., Sungkyunkwan University, Yonsei University |
| NCT05143463 | Phase 1 | Nov 4, 2021 | Neuracle Science Co., LTD., Syneos Health |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neuracle Science Co., LTD. | For profit | 2 | 2 | 2 | 2021 |
| Yonsei University | Academic/Hospital | 2 | 0 | 1 | 2024 |
| Hanyang University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Konkuk University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Korea University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Syneos Health | For profit | 1 | 0 | 1 | 2021 |
| University of Ulsan | Academic/Hospital | 1 | 0 | 1 | 2025 |
8 organizations
Page 1 / 1